BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

...shares, a postmoney valuation of $445.6 million. BC Staff Molecular Partners AG Biodesix Inc. Novartis AG insitro Gracell Biotechnologies Genecast Biotechnology PureTech Health plc Cerevel Therapeutics LLC Mirati...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...SPAC’s original IPO price.Other mergers like Nuvation, Cerevel Therapeutics LLC...
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...Coles announced plans to take neuroscience company Cerevel Therapeutics LLC...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...well, selling 13 million shares at $10. Its two Perceptive-backed SPAC predecessors have merged with Cerevel Therapeutics LLC...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...of biotechs to land on public markets in recent months, including a large deal with Cerevel Therapeutics LLC...
BioCentury | Aug 4, 2020
Product Development

Warp Speed, decentralized trials & SPACs: a BioCentury podcast

...find the next biotech unicorn. They may have found it, says Cranmer, after Tony Coles’ Cerevel Therapeutics LLC...
...in addition to Spotify, Apple Podcasts , Google Podcasts and Stitcher . BC Staff AstraZeneca plc GlaxoSmithKline plc Cerevel Therapeutics LLC podcast chs2020 covid-19 cov19count cov19pol drug...
BioCentury | Jul 31, 2020
Finance

AlloVir carries July’s IPO haul beyond $2.5B

...NASDAQ IPOs during July, the majority have raised more than $200 million. Also on Thursday, Cerevel Therapeutics LLC...
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

...companies that are set up to merge with private companies after themselves going public. In Cerevel Therapeutics LLC’s...
...to NASDAQ”). Targets DRD1 - Dopamine D1 receptor DRD5 - Dopamine D5 receptor Paul Bonanos, Associate Editor Cerevel Therapeutics LLC Perceptive...
BioCentury | Jul 30, 2020
Deals

F-Star lands on NASDAQ sooner than expected via reverse merger

...the only company to clear a route to NASDAQ Thursday via a less traditional path. Cerevel Therapeutics LLC...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...become CFO, succeeding interim CFO David Socks. Branning was CFO of Amneal Pharmaceuticals Inc. (NYSE:AMRX). Cerevel Therapeutics LLC...
...Staff Waters Corp. Vertex Pharmaceuticals Inc. Turning Point Therapeutics Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn Therapeutics Inc. Cerevel Therapeutics LLC Phathom...
Items per page:
1 - 10 of 29
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

...shares, a postmoney valuation of $445.6 million. BC Staff Molecular Partners AG Biodesix Inc. Novartis AG insitro Gracell Biotechnologies Genecast Biotechnology PureTech Health plc Cerevel Therapeutics LLC Mirati...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...SPAC’s original IPO price.Other mergers like Nuvation, Cerevel Therapeutics LLC...
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...Coles announced plans to take neuroscience company Cerevel Therapeutics LLC...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...well, selling 13 million shares at $10. Its two Perceptive-backed SPAC predecessors have merged with Cerevel Therapeutics LLC...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...of biotechs to land on public markets in recent months, including a large deal with Cerevel Therapeutics LLC...
BioCentury | Aug 4, 2020
Product Development

Warp Speed, decentralized trials & SPACs: a BioCentury podcast

...find the next biotech unicorn. They may have found it, says Cranmer, after Tony Coles’ Cerevel Therapeutics LLC...
...in addition to Spotify, Apple Podcasts , Google Podcasts and Stitcher . BC Staff AstraZeneca plc GlaxoSmithKline plc Cerevel Therapeutics LLC podcast chs2020 covid-19 cov19count cov19pol drug...
BioCentury | Jul 31, 2020
Finance

AlloVir carries July’s IPO haul beyond $2.5B

...NASDAQ IPOs during July, the majority have raised more than $200 million. Also on Thursday, Cerevel Therapeutics LLC...
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

...companies that are set up to merge with private companies after themselves going public. In Cerevel Therapeutics LLC’s...
...to NASDAQ”). Targets DRD1 - Dopamine D1 receptor DRD5 - Dopamine D5 receptor Paul Bonanos, Associate Editor Cerevel Therapeutics LLC Perceptive...
BioCentury | Jul 30, 2020
Deals

F-Star lands on NASDAQ sooner than expected via reverse merger

...the only company to clear a route to NASDAQ Thursday via a less traditional path. Cerevel Therapeutics LLC...
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...become CFO, succeeding interim CFO David Socks. Branning was CFO of Amneal Pharmaceuticals Inc. (NYSE:AMRX). Cerevel Therapeutics LLC...
...Staff Waters Corp. Vertex Pharmaceuticals Inc. Turning Point Therapeutics Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn Therapeutics Inc. Cerevel Therapeutics LLC Phathom...
Items per page:
1 - 10 of 29